CD BioGlyco provides an integrated solution to develop carbohydrate-based vaccines according to each customer's scientific project. We have various advanced technology platforms and high-quality services to meet your requirements. We have confidence to be your essential research assistant in the field of glycobiology.
Avery and Heidelberger discovered that capsular polysaccharide (CPS) of Streptococcus pneumoniae was immunoreactive in the 1920s, which was the starting point for the development of carbohydrate-based vaccines. Vaccination is an effective and safe strategy to prevent infections caused by pathogens. Since most bacterial pathogens have dense polysaccharide arrays on their surfaces, carbohydrate-based vaccine methods have been applied to many bacterial strains. Although the natural CPS vaccine can effectively control the incidence of diseases in adults, there are still some disturbing immune deficiencies. For example, Hib CPS vaccine does not elicit a protective antibody response in children below the age of 2 years and people with weakened immune systems. To overcome these problems, vaccine researchers have focused their research on improving the immunogenicity of oligosaccharides.
As a result, studies have shown that the conjugation of oligosaccharides and immunogenic carrier proteins can improve the immunogenicity of the vaccine, and the first glycoconjugate vaccine against Hib was introduced in 1987. Consequently, most countries incorporate these carbohydrate-based vaccines into their routine immunization program. With the successful application of antibacterial glycoconjugate vaccines, researchers have further developed carbohydrate-based conjugate vaccines for viruses, protozoa, fungi and cancer.
Fig 1. Current focus of research: carbohydrate-based vaccines against a variety of diseases (Hütter, J.; Lepenies, B. 2015)
CD BioGlyco offers three strategies to construct carbohydrate-based vaccines.
Most licensed carbohydrate-based vaccines, such as Streptococcus pneumoniae, Neisseria meningitidis belong to this category, where carbohydrate antigens are isolated from microbial cultures. We can provide complex purification procedures and analytical tests. However, problems such as heterogeneous composition and cellular impurities can occur when using this method.
Advances in carbohydrate synthetic chemistry have made it possible to synthesize complex oligosaccharides on a large scale. Certain antigens are limited in quantity and the purification process is extremely difficult. In this case, the antigens can be produced in large quantities through synthetic chemistry. The advantages of synthetic vaccines include homogeneity, higher purity and better safety.
The third type of glycoconjugate vaccine includes not only chemically synthesized carbohydrate antigens, but also synthetic peptide carriers. Most vaccines developed for cancer and viruses fall into this category. We have a variety of professional platforms to synthesize oligosaccharides and peptide carriers. These synthetic vaccines have high immunogenicity.
The carrier proteins we provide include but are not limited to BSA, KLH, DT, TT, CRM197, OVA, MUC1 peptides, HSA, rEPA, etc. To better conjugate the antigen to the carrier protein, you can also choose to install spacers between them, including maleimide, p-nitrophenyl, and aldehyde containing groups, which then conjugated to the carriers through Michael addiction, amide bonds, and reductive amination.
CD BioGlyco is committed to providing high-quality carbohydrate-based vaccine design and synthesis services to promote the progress of customer vaccine development projects. Our experienced scientific research personnel will customize a rational program according to your needs, and finally obtain carbohydrate antigens with a certain structure and high immunogenicity.
Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.